The following video is part of a special series in which Motley Fool analyst Andrew Tonner and "Options Whiz"?Jeff Fischer discuss how to make 2012 the year YOU master the market.
In this edition, Andrew and Jeff analyze General Electric, and Jeff explains an uncommon way to profit off of GE.
For more details on how to trade General Electric using similar options strategies with as much potential or more, just click here.
You'll be directed to the Motley Fool Options Whiz -- our interactive "Options U" designed to teach you to trade options sensibly, with a minimum of risk, and all the resources of The Motley Fool behind you -- all 100% FREE!
Related Articles:Poniard Pharmaceuticals Announces Licensing Agreement for Focal Adhesion Kinase Technology
Top 10 Pre-Market Analyst Calls (ADBE, CRUS, DVA, EEQ, EQR, IP, LNCR, RGLD, WIN, BRL, MFLX, MYL, TEVA, WPI)
Tags: ALLOZYNE ,biopharmaceutical company ,FAK technology ,focal adhesion kinase technology ,licensing agreement ,metastases ,NASDAQ:PARD ,novel inhibitors ,oncology products ,PARD ,picoplatin ,platinum-based cancer therapy ,Poniard Pharmaceuticals ,proliferation of cancer ,protein tyrosine kinase 2 ,Ronald A Martell ,Scripps Research Institute ,tumor cells ,Best China Stocks 2012
No comments:
Post a Comment